{"id":3185,"date":"2014-03-31T06:30:00","date_gmt":"2014-03-31T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xps-systemet-har-erhallit-ce-marke\/"},"modified":"2014-03-31T06:30:00","modified_gmt":"2014-03-31T06:30:00","slug":"xps-systemet-har-erhallit-ce-marke","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/","title":{"rendered":"XPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke"},"content":{"rendered":"
XVIVO Perfusion har erh\u00e5llit CE-m\u00e4rke p\u00e5 sin nyutvecklade apparatur f\u00f6r lungperfusion, XPS\u2122 (Xvivo Perfusion System). Detta m\u00f6jligg\u00f6r f\u00f6rs\u00e4ljning av XPS\u2122 och tillh\u00f6rande eng\u00e5ngsartiklar i Europa.<\/strong><\/div>\n

XVIVO Perfusion AB (publ) har sedan 2009 utvecklat ett komplett system f\u00f6r att underl\u00e4tta ex vivo lung perfusion (EVLP) med STEEN Solution\u2122. XPS\u2122 \u00e4r med sin integrerade Hamilton C2 ventilator och MAQUET CardioHelp centrifugalpump marknadens mest flexibla och kompletta plattform f\u00f6r EVLP och ger transplantationsteamet full kontroll \u00f6ver hela processen. Systemets flexibilitet ger anv\u00e4ndaren m\u00f6jlighet att v\u00e4lja s\u00e5v\u00e4l ventilations och perfusionsstrategi enligt klinikens \u00f6nskade protokoll. <\/span><\/p>\n

XPS\u2122-designen inneb\u00e4r dessutom att r\u00f6ntgen eller CT scanning kan g\u00f6ras under p\u00e5g\u00e5ende EVLP utv\u00e4rdering utan avbrott i proceduren. XPS\u2122 har ett anv\u00e4ndarv\u00e4nligt grafiskt gr\u00e4nssnitt med touchscreen-funktionalitet och dataregistrering av lungans v\u00e4rden under hela EVLP-proceduren ger underlag till analys och utv\u00e4rdering inf\u00f6r slutligt kliniskt beslut om anv\u00e4ndande av organet. XPS\u2122 med STEEN Solution\u2122 m\u00f6jligg\u00f6r att fler lungor kan anv\u00e4ndas till transplantation, vilket g\u00f6r att fler sv\u00e5rt lungsjuka patienter erh\u00e5ller h\u00f6gre livskvalitet och ett l\u00e4ngre liv.<\/span><\/p>\n

XPS\u2122 anv\u00e4nds med goda kliniska resultat p\u00e5 ledande kliniker i USA inom ramen f\u00f6r NOVEL studien. EVLP med STEEN Solution\u2122 har anv\u00e4nts vid mer \u00e4n 300 lungtransplantationer vid n\u00e4rmare 30 kliniker, som till exempel Wien, Paris, Toronto med flera, och har d\u00e4r uppvisat liknande stabila resultat som de XVIVO Perfusion nyligen offentliggjort fr\u00e5n den amerikanska NOVEL studien (se press release den 21 mars 2014).<\/span><\/p>\n

\u201dVi kan nu tillm\u00f6tesg\u00e5 v\u00e5ra kunders \u00f6nskem\u00e5l om ett flexibelt och s\u00e4kert system f\u00f6r EVLP. De goda kliniska resultat och det stora antalet transplantationer som skett med STEEN Solution\u2122 och Toronto-metoden har resulterat i det stora intresse vi har bland kliniker i Europa. \u201ds\u00e4ger XVIVO Perfusions VD Magnus Nilsson. <\/span><\/p>\n

G\u00f6teborg 31 mars 2014
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO<\/span><\/p>\n

\n

F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n

Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: christoffer.rosenblad@xvivoperfusion.com<\/a>
F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/a><\/span><\/p>\n

XVIVO Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a031 mars 2014 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

XVIVO Perfusion har erh\u00e5llit CE-m\u00e4rke p\u00e5 sin nyutvecklade apparatur f\u00f6r lungperfusion, XPS\u2122 (Xvivo Perfusion System). Detta m\u00f6jligg\u00f6r f\u00f6rs\u00e4ljning av XPS\u2122…<\/p>\n","protected":false},"template":"","class_list":["post-3185","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"\nXPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke - XVIVO\" \/>\n<meta property=\"og:description\" content=\"XVIVO Perfusion har erh\u00e5llit CE-m\u00e4rke p\u00e5 sin nyutvecklade apparatur f\u00f6r lungperfusion, XPS\u2122 (Xvivo Perfusion System). Detta m\u00f6jligg\u00f6r f\u00f6rs\u00e4ljning av XPS\u2122...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-systemet-har-erhallit-ce-marke\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-systemet-har-erhallit-ce-marke\\\/\",\"name\":\"XPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2014-03-31T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-systemet-har-erhallit-ce-marke\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-systemet-har-erhallit-ce-marke\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-systemet-har-erhallit-ce-marke\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/","og_locale":"en_US","og_type":"article","og_title":"XPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke - XVIVO","og_description":"XVIVO Perfusion har erh\u00e5llit CE-m\u00e4rke p\u00e5 sin nyutvecklade apparatur f\u00f6r lungperfusion, XPS\u2122 (Xvivo Perfusion System). Detta m\u00f6jligg\u00f6r f\u00f6rs\u00e4ljning av XPS\u2122...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/","name":"XPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2014-03-31T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-systemet-har-erhallit-ce-marke\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XPS\u2122 systemet har erh\u00e5llit CE-m\u00e4rke"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}